EnglishСочетание антитромботических и фибринолитических препаратов. Стоит ли назначать?
П. Катри, М.-Л. Моно
Department of Neurology, University of Cincinnati, Cincinnati, OH; Department of Neurology, Inselspital, University Hospital and University of Bern, Switzerland.
Подписка
Литература
1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. 121495 Tissue Plasminogen Activator for Acute Ischemic Stroke. 2000; 1–7.
2. Lees K.R., Bluhmki E., von Kummer R., Brott T.G., Toni D., Grotta J.C., et al. ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695–1703.
3. Alexandrov A.V., Demchuk A.M., Burgin W.S., Robinson D.J., Grotta J.C. CLOTBUST Investigators. Ultrasound-enhanced thrombolysis for acute ischemic stroke: phase I. Findings of the CLOTBUST trial. J Neuroimaging. 2004;14:113–117.
4. Marks M.P., Olivot J.M., Kemp S., Lansberg M.G., Bammer R., Wechsler L.R., et al. Patients with acute stroke treated with intravenous tPA 3–6 hours after stroke onset: correlations between MR angiography findings and perfusion- and diffusion-weighted imaging in the DEFUSE study. Radiology. 2008; 249: 614–623.
5. Mendonça N., Rodriguez-Luna D., Rubiera M., Boned-Riera S., Ribo M., Pagola J., et al. Predictors of tissue-type plasminogen activator nonresponders according to location of vessel occlusion. Stroke.2012;43:417–421.
6. Bhatia R., Hill M.D., Shobha N., Menon B., Bal S., Kochar P., et al.
Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke. 2010;41:2254–2258.
7. Olivot J.M., Mlynash M., Thijs V.N., Kemp S., Lansberg M.G., Wechsler L., et al. Relationships between infarct growth, clinical outcome, and early recanalization in diffusion and perfusion imaging for understanding stroke evolution (DEFUSE). Stroke. 2008;39:2257–2263.
8. Lees K.R., Bluhmki E., von Kummer R., Brott T.G., Toni D., Grotta J.C., et al. ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.Lancet. 2010;375:1695–1703.
9. Alexandrov A.V., Grotta J.C. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology. 2002;59:862–867.
10. Rubiera M., Alvarez-Sabín J., Ribo M., Montaner J., Santamarina E., Arenillas J.F., et al. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke. 2005;36:1452–1456.
11. Saqqur M., Molina C.A., Salam A., Siddiqui M., Ribo M., Uchino K.,
et al. CLOTBUST Investigators. Clinical deterioration after intravenous recombinant tissue plasminogen activator treatment: a multicenter transcranial Doppler study. Stroke. 2007;38:69–74.
12. Interventional Management of Stroke III Trial (IMS III). NINDS Clinical Trials. http://www.ninds.nih.gov/disorders/clinical_trials/NCT00359424. htm. Accessed November 6, 2012.
13. Field Administration of Stroke Therapy-Magnesium (FAST-MAG) Trial, ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT0005933 2?term=fast+mag+stroke&rank=114. Accessed November 6, 2012.
14. Zinkstok S.M., Roos Y.B. ARTIS Investigators. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet. 2012;380:731–737.
15. Diedler J., Ahmed N., Sykora M., Uyttenboogaart M., Overgaard K., Luijckx G.J., et al. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke. 2010;41:288–294.
16. Cucchiara B., Kasner S.E., Tanne D., Levine S.R., Demchuk A., Messe S.R., et al. SAINT Investigators. Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials. Stroke. 2009;40:3067–3072.
17. Larrue V., von Kummer R.R., Muller A., Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32:438–441.
18. del Zoppo G.J., Higashida R.T., Furlan A.J., Pessin M.S., Rowley H.A., Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke. 1998;29:4–11.
19. Rebeiz A.G., Johanson P., Green C.L., Crater S.W., Roe M.T.., Langer A., et al. Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). Am J Cardiol. 2005;95:611–614.
20. Khatri P., Abruzzo T.A., Yeatts S.D., Broderick J.P., Tomsick T.A. for the IMS I and II Investigators. Good outcome after successful intra-arterial therapy is time-dependent. Neurology. 2009; 73:1066–1072.
21. Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-ER). ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT00894803?term=clearer+stroke&rank=1. Accessed November 6, 2012.
22. Jang I.K., Brown D.F., Giugliano R.P., Anderson H.V., Losordo D., Nicolau J.C., et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol. 1999;33:
1879–1885.
23. Randomized Controlled Trial of Argatroban With tPA for Acute Stroke (ARTSS-2). ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/show/NCT 01464788?term=argatroban+stroke&rank=2. Accessed November 6, 2012.
24. Pancioli A., Broderick J.P., Brott T., Tomsick T.A., Khoury J.C., Bean J., et al. The Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (The CLEAR Stroke Trial). Stroke. 2008;39:3268–3276.
25. Barreto A.D., Alexandrov A.V., Lyden P., Lee J., Martin-Schild S., Shen L., et al. The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study. Stroke. 2012;43:
770–775.
Похожие статьи
